Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels
Highlights • Structure of PCSK9/CHRD and an inhibitory nanobody that prevents LDLR degradation.• Binding of CAP1 to PCSK9 enhances its activity and abrogates nanobody inhibition.•